Scholarlink

<p>No sex-based data are available on the pharmacodynamic and pharmacokinetic profile of ticagrelor 60&#xa0;mg twice daily as alternative to its standard dose during the early phase after acute coronary syndrome (ACS). This post-hoc study is a sex-based secondary analysis of the PLINY THE ELDER randomized, crossover trial (NCT04739384), which compared ticagrelor 60 vs. 90&#xa0;mg in elderly patients with ACS undergoing percutaneous coronary intervention (PCI). The primary endpoint was the pre-dose P2Y<sub>12</sub> reaction units (PRU) using the VerifyNow-P2Y<sub>12</sub> (Accumetrics, San Diego, CA, USA) at 14 days after treatment with ticagrelor 60 or 90&#xa0;mg twice daily. A total of 50 elderly patients with ACS was included in the study. Of these patients, 28 (56%) were males and 22 (44%) females. The two doses of ticagrelor had a comparable PRU in both males (pre-dose: LSM difference<sub>60 vs. 90</sub> -7.00, 95%CI -25.3 to 11.3, <i>p</i> = 0.44; post-dose: LSM difference<sub>60 vs. 90</sub> 3.90, 95%CI -10.6 to 18.5, <i>p</i> = 0.59) and females (pre-dose: LSM difference<sub>60 vs. 90</sub> -0.89, 95%CI -20.3 to 18.5, <i>p</i> = 0.93; post-dose: LSM difference<sub>60 vs. 90</sub> -1.10, 95%CI -16.6 to 14.3, <i>p</i> = 0.88), with no evidence of sex-based interaction (pre-dose: p for interaction = 0.88; post-dose: p for interaction = 0.65). Consistently, transmittance aggregometry and multiple electrode aggregometry showed a similar pharmacodynamic profile between the two doses of ticagrelor in both male and female patients. Plasma levels of ticagrelor were significantly lower using the reduced dose of ticagrelor as compared with the standard dose in both males (pre-dose: LSM difference<sub>60 vs. 90</sub> -212, 95%CI -391 to -33.0, <i>p</i> &lt; 0.002; post-dose: LSM difference<sub>60 vs. 90</sub> -308, 95%CI -510 to -105, <i>p</i> = 0.004) and females (pre-dose: LSM difference<sub>60 vs. 90</sub> -131, 95%CI -332 to 69.1, <i>p</i> = 0.19; post-dose: LSM difference<sub>60 vs. 90</sub> -670, 95%CI -898 to -442, <i>p</i> &lt; 0.001). Ticagrelor 60&#xa0;mg and ticagrelor 90 twice daily yielded the same magnitude of platelet inhibition among elderly patients with ACS irrespective of sex.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sex differences among elderly ACS patients undergoing percutaneous coronary intervention receiving Ticagrelor 60 mg vs. 90 mg

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月16日

查看全文
  • Raffaele Piccolo,
  • Angelo Laino,
  • Antonio Pio Vitale,
  • Mario Enrico Canonico,
  • Marisa Avvedimento,
  • Fiorenzo Simonetti,
  • Roberta Paolillo,
  • Fabrizio Dal Piaz,
  • Bruno Charlier,
  • Alessandra Spinelli,
  • Stefano Cristiano,
  • Luigi Di Serafino,
  • Plinio Cirillo,
  • Giuseppe Gargiulo,
  • Anna Franzone,
  • Amelia Filippelli,
  • Valeria Conti,
  • Giovanni Esposito

摘要

No sex-based data are available on the pharmacodynamic and pharmacokinetic profile of ticagrelor 60 mg twice daily as alternative to its standard dose during the early phase after acute coronary syndrome (ACS). This post-hoc study is a sex-based secondary analysis of the PLINY THE ELDER randomized, crossover trial (NCT04739384), which compared ticagrelor 60 vs. 90 mg in elderly patients with ACS undergoing percutaneous coronary intervention (PCI). The primary endpoint was the pre-dose P2Y12 reaction units (PRU) using the VerifyNow-P2Y12 (Accumetrics, San Diego, CA, USA) at 14 days after treatment with ticagrelor 60 or 90 mg twice daily. A total of 50 elderly patients with ACS was included in the study. Of these patients, 28 (56%) were males and 22 (44%) females. The two doses of ticagrelor had a comparable PRU in both males (pre-dose: LSM difference60 vs. 90 -7.00, 95%CI -25.3 to 11.3, p = 0.44; post-dose: LSM difference60 vs. 90 3.90, 95%CI -10.6 to 18.5, p = 0.59) and females (pre-dose: LSM difference60 vs. 90 -0.89, 95%CI -20.3 to 18.5, p = 0.93; post-dose: LSM difference60 vs. 90 -1.10, 95%CI -16.6 to 14.3, p = 0.88), with no evidence of sex-based interaction (pre-dose: p for interaction = 0.88; post-dose: p for interaction = 0.65). Consistently, transmittance aggregometry and multiple electrode aggregometry showed a similar pharmacodynamic profile between the two doses of ticagrelor in both male and female patients. Plasma levels of ticagrelor were significantly lower using the reduced dose of ticagrelor as compared with the standard dose in both males (pre-dose: LSM difference60 vs. 90 -212, 95%CI -391 to -33.0, p < 0.002; post-dose: LSM difference60 vs. 90 -308, 95%CI -510 to -105, p = 0.004) and females (pre-dose: LSM difference60 vs. 90 -131, 95%CI -332 to 69.1, p = 0.19; post-dose: LSM difference60 vs. 90 -670, 95%CI -898 to -442, p < 0.001). Ticagrelor 60 mg and ticagrelor 90 twice daily yielded the same magnitude of platelet inhibition among elderly patients with ACS irrespective of sex.

Graphical abstract